Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party

It is often difficult to continue treatment with hypomethylating agent(HMA) in clinical practice because of problems such as toxicities, poor economics, etc. We compared clinical outcomes of those patients who continued HMA and those who discontinued HMA because of other causes, and evaluated factor...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Kim, Da Jung, Lee, Ho Sup, Moon, Joon-Ho, Sohn, Sang Kyun, Kim, Hyeoung Joon, Cheong, June-Won, Jo, Deog-Yeon, Kim, Hawk, Lee, Hyewon, Bang, Soo-Mee, Lee, Won Sik, Park, Yong, Lee, Mark Hong, Lee, Jae Hoon, Bae, Sung Hwa, Kim, Min Kyoung
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2017
Soggetti:
Clinical Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5668053/
https://ncbi.nlm.nih.gov/pubmed/29108320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18258
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi